The expression vectors market is expected to reach $317.1 Million by 2020 from $242.7 Million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. Major factors driving the growth of this market include the increasing demand of protein-based drugs (biologics); high prevalence of lifestyle diseases, infectious diseases, and genetic disorders; and increasing funding for protein research. On the other hand, high market consolidation, which increases entry barriers, and high cost of protein therapy are the major factors restraining the growth of this market.

North America dominates this market, with the U.S. accounting for a major market share. However, the Asian market is poised to grow at the highest CAGR during the forecast period. Growth in the Asian market will be driven by factors such as high growth in the pharmaceutical and biotechnology sector, presence of key market players in this region, and changing regulatory framework to support innovation and commercialization.

By End User

By Region

North America

U.S.

Canada

Europe

Asia

Rest of the World (RoW)

An expression vector/expression construct is a plasmid or virus used for protein expression in different types of host cells. An expression vector helps to introduce a gene of interest into a target cell and triggers the cells mechanism to produce a protein encoded by the gene. This is a slow-growing market whose growth is mainly driven by the increasing demand of protein-based drugs (biologics); high prevalence of lifestyle diseases, infectious diseases, and genetic disorders; and increasing funding for protein research and protein therapy. On the other hand, high market consolidation, which increases entry barriers, and high cost of protein therapy are the major factors restraining the growth of this market. However, high growth potential in emerging economies provides new growth opportunities to players in this market.

The expression vectors market is expected to reach $317.1 Million by 2020 from $242.7 Million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. This market is segmented on the basis of host type, application, end user, and region.

On the basis of host type, this market is segmented into bacterial, mammalian, insect, yeast, and other expression vectors. Bacterial expression vectors are further segmented into expression vectors for E. Coli and other bacterial expression vectors. The mammalian expression vectors market is further segmented into expression vectors for CHO systems and other mammalian expression vectors. The insect expression vectors market is segmented into expression vectors for Baculovirus systems and other insect expression vectors. The yeast expression vectors market is segmented into expression vectors for K. lactis systems, Pichia pastoris systems, Saccharomyces cerevisiae systems, and other yeast systems.

On the basis of application, this global market is segmented into therapeutic, research, and industrial applications. On the basis of end users, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs) and contract manufacturing organization (CMOs), academic research institutes, and other end users.

The global market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period. However, Asia is poised to grow at the highest CAGR in the forecast period. Over the next five years, growth in the Asian region is likely to be centered on China and India.